Inhibikase Therapeutics, Inc. Annual Costs and Expenses in USD from 2020 to 2023

Taxonomy & unit
us-gaap: USD
Description
Total costs of sales and operating expenses for the period.
Summary
Inhibikase Therapeutics, Inc. quarterly/annual Costs and Expenses history and growth rate from 2020 to 2023.
  • Inhibikase Therapeutics, Inc. Costs and Expenses for the quarter ending June 30, 2024 was $5.05M, a 20.1% decline year-over-year.
  • Inhibikase Therapeutics, Inc. Costs and Expenses for the twelve months ending June 30, 2024 was $19.1M, a 4.66% decline year-over-year.
  • Inhibikase Therapeutics, Inc. annual Costs and Expenses for 2023 was $20.4M, a 11.5% increase from 2022.
  • Inhibikase Therapeutics, Inc. annual Costs and Expenses for 2022 was $18.3M, a 2.16% increase from 2021.
  • Inhibikase Therapeutics, Inc. annual Costs and Expenses for 2021 was $17.9M, a 408% increase from 2020.
Costs and Expenses, Trailing 12 Months (USD)
Costs and Expenses, Annual (USD)
Costs and Expenses, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 $20.4M +$2.1M +11.5% Jan 1, 2023 Dec 31, 2023 10-K 2024-03-27
2022 $18.3M +$385K +2.16% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-27
2021 $17.9M +$14.3M +408% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-31
2020 $3.52M Jan 1, 2020 Dec 31, 2020 10-K 2022-03-31
* An asterisk sign (*) next to the value indicates that the value is likely invalid.